These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25009791)

  • 1. Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review.
    Manatsathit W; Al-Hamid H; Leelasinjaroen P; Hashmi U; McCullough PA
    Cardiovasc Diagn Ther; 2014 Jun; 4(3):224-31. PubMed ID: 25009791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Retrospective Review of Upper Gastrointestinal Bleed Outcomes During Hospital Admission While on Oral Anticoagulation.
    Scibelli N; Mangano A; Raynor K; Wilson S; Singh P
    Cureus; 2021 May; 13(5):e15061. PubMed ID: 34150404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation.
    Flack KF; Desai J; Kolb JM; Chatterjee P; Wallentin LC; Ezekowitz M; Yusuf S; Connolly S; Reilly P; Brueckmann M; Ilgenfritz J; Aisenberg J
    Clin Gastroenterol Hepatol; 2017 May; 15(5):682-690. PubMed ID: 27765728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran for stroke prevention in nonvalvular atrial fibrillation: focus in the geriatric population.
    Brunetti L; Chen C; White J
    Consult Pharm; 2014 Mar; 29(3):169-78. PubMed ID: 24589766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
    Wallentin L; Yusuf S; Ezekowitz MD; Alings M; Flather M; Franzosi MG; Pais P; Dans A; Eikelboom J; Oldgren J; Pogue J; Reilly PA; Yang S; Connolly SJ;
    Lancet; 2010 Sep; 376(9745):975-83. PubMed ID: 20801496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
    Eikelboom JW; Wallentin L; Connolly SJ; Ezekowitz M; Healey JS; Oldgren J; Yang S; Alings M; Kaatz S; Hohnloser SH; Diener HC; Franzosi MG; Huber K; Reilly P; Varrone J; Yusuf S
    Circulation; 2011 May; 123(21):2363-72. PubMed ID: 21576658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
    Dans AL; Connolly SJ; Wallentin L; Yang S; Nakamya J; Brueckmann M; Ezekowitz M; Oldgren J; Eikelboom JW; Reilly PA; Yusuf S
    Circulation; 2013 Feb; 127(5):634-40. PubMed ID: 23271794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
    Villines TC; Schnee J; Fraeman K; Siu K; Reynolds MW; Collins J; Schwartzman E
    Thromb Haemost; 2015 Nov; 114(6):1290-8. PubMed ID: 26446456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal bleeding with dabigatran, a comparative study with warfarin: a multicenter experience.
    Sherid M; Sifuentes H; Sulaiman S; Samo S; Husein H; Tupper R; Spurr C; Sridhar S
    Korean J Gastroenterol; 2015 Apr; 65(4):205-14. PubMed ID: 25896154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Garnock-Jones KP
    Am J Cardiovasc Drugs; 2011; 11(1):57-72. PubMed ID: 21265583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locations and Mucosal Lesions Responsible for Major Gastrointestinal Bleeding in Patients on Warfarin or Dabigatran.
    Kolb JM; Flack KF; Chatterjee-Murphy P; Desai J; Wallentin LC; Ezekowitz M; Connolly S; Reilly P; Brueckmann M; Ilgenfritz J; Aisenberg J
    Dig Dis Sci; 2018 Jul; 63(7):1878-1889. PubMed ID: 29582237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dabigatran etexilate: An alternative to warfarin for patients with nonvalvular atrial fibrillation.
    Scott KA; Amirehsani KA
    J Am Assoc Nurse Pract; 2015 Apr; 27(4):190-6. PubMed ID: 25066647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Bleeding Events Requiring Hospitalization in Patients With Atrial Fibrillation Receiving Dabigatran, Warfarin, or Antiplatelet Therapy.
    Riley TR; Gauthier-Lewis ML; Sanchez CK; Riley TT
    J Pharm Pract; 2017 Apr; 30(2):214-218. PubMed ID: 26951615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spotlight on dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Garnock-Jones KP
    Drugs Aging; 2011 May; 28(5):415-9. PubMed ID: 21542663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of Gastrointestinal Bleeding in Patients Treated with Direct-Acting Oral Anticoagulants.
    Brodie MM; Newman JC; Smith T; Rockey DC
    Am J Med; 2018 May; 131(5):573.e9-573.e15. PubMed ID: 29175237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes.
    Rubin TA; Murdoch M; Nelson DB
    Gastrointest Endosc; 2003 Sep; 58(3):369-73. PubMed ID: 14528210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
    Langkilde LK; Bergholdt Asmussen M; Overgaard M
    J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.
    Oldgren J; Alings M; Darius H; Diener HC; Eikelboom J; Ezekowitz MD; Kamensky G; Reilly PA; Yang S; Yusuf S; Wallentin L; Connolly SJ;
    Ann Intern Med; 2011 Nov; 155(10):660-7, W204. PubMed ID: 22084332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial.
    Hart RG; Diener HC; Yang S; Connolly SJ; Wallentin L; Reilly PA; Ezekowitz MD; Yusuf S
    Stroke; 2012 Jun; 43(6):1511-7. PubMed ID: 22492518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.